AiLNP

AiRNA

AiTEM

AI驱动`药物递送`和`药物发现`

AI-Driven `Drug Delivery` and `Drug Discovery`

METiS Pharmaceuticals, an innovative biotechnology company focusing on &quot;AI + drug delivery,&quot; announced the appointment of Dr. Wei Xu as Chief Scientific Officer. Dr. Xu will lead drug discovery and translational efforts to advance the mRNA-based therapeutics to the clinical stage. Dr. Xu will also work with the management team to establish high-value pipeline. <div class="media-wrap image-wrap align-center" style="text-align:center"><img class="media-wrap image-wrap align-center" src="https://oss.metispharmaceuticals.cn/b50b68383d77f0ef60c3dabf33342cd8.jpg" width="160.333px" height="213px" style="width:160.333px;height:213px"/></div>Dr. Wei Xu, CSO of METiS PharmaceuticalsDr. Xu possesses a strong academic and industrial background in various therapeutic fields including immunology, oncology, and cell therapy. He has held positions at multiple renowned companies, demonstrating a wealth of experience in research and development management.His academic career began at Leiden University Medical Center in the Netherlands, where he obtained his doctoral degree in Immunology in 2007. Subsequently, he joined the Baylor Institute for Immunology Research (Dallas) as a postdoctoral fellow. During his tenure at Roche Innovation Center Zurich (Switzerland), he has enabled 4 immunotherapy NMEs into clinical development. From 2018 to 2022, Dr. Xu served as Vice President and Head of New Drug Biology &amp; Translational Medicine at Innovent Biologics (Suzhou), where he built teams focused on novel biologics and translational medicine. He led the transformation of the company’s R&amp;D capabilities from “me-too” drugs to FIC and BIC drugs and even built cell therapy capability from scratch. He then returned to Switzerland and joined Numab Therapeutics as CSO, responsible for driving and executing the overall strategy in research and development pipeline, where he managed Drug discovery, Antibody discovery, CMC, and translational science teams.Dr. Xu Wei stated, &quot;I am extremely honored to join METiS Pharmaceuticals, a team full of vitality and innovative spirit. METiS has created the world&#x27;s first and best-in-class AI-driven drug delivery platform, tissue targeted lipid nanoparticles (LNP), opening up immense possibilities for the next generation of mRNA-encoded immunotherapy. I look forward to working with METiS’ Team to build innovative drug pipelines that are globally competitive.&quot;Hongming Chen, Sc.D., President and Head of R&amp;D warmly welcomes Dr. Xu &#x27;s joining, &quot;Dr. Xu is a world-class expert in drug discovery. His extensive experience and outstanding abilities will bring new impetus and vitality to our research and development efforts. We believe that under his leadership, our Drug Discovery Department will achieve greater breakthroughs, accelerating the development of the mRNA pipeline and developing more effective therapeutic drugs for patients worldwide.&quot;Dr. Chris Lai, co-founder &amp; CEO of METiS Pharmaceuticals, also expresses great anticipation for Dr. Xu&#x27;s joining, &quot;Dr. Xu&#x27;s joining infuses METiS with formidable research and development capabilities. As an innovative biotechnology company committed to advancing AI drug delivery and discovery, we have made significant progress in the field of small molecule drugs, with the fastest in Phase III clinical trials. Additionally, mRNA pipelines constitute our next strategic focus. We look forward to achieving greater achievements in drug development under Dr. Xu&#x27;s leadership at METiS.&quot; About METiS PharmaceuticalsMETiS Pharmaceuticals is an innovative biotechnology company driven by AI that harnesses targeted drug delivery and discovery technology to develop more effective drugs for patients. Through the integration of cutting-edge AI technology and traditional pharmaceutical R&amp;D, METiS aims to accelerate the R&amp;D of innovative drugs in a more efficient and precise way, while leveraging the core technology platforms to support the entire pharmaceutical ecosystem and lead industry innovation.METiS was founded and led by Hongming Chen, a member of the National Academy of Engineering; Dr. Chris Lai and Dr. Wenshou Wang, top scientists from MIT. On top of drug development experts from major pharmaceutical companies such as Regeneron, Amgen, and Novartis, we also host young talents in AI and computing.METiS has built 3 unique core-technology platforms: AiLNP (AI-driven RNA Delivery Design Platform), AiRNA (AI-driven mRNA design and synthesis platform), and AiTEM (AI-driven Small Molecule Formulation Design Platform). Based on these platforms, METiS has developed a portfolio of over 10 drugs, including small molecule and RNA drugs. Going forward, METiS will focus on RNA drugs and other innovative therapies with more challenging drug-delivery requirements to drive technological breakthroughs.

METiS Pharmaceuticals announced the appointment of Dr. Wei Xu as Chief Scientific Officer. Dr. Xu will lead drug discovery and translational efforts to advance the mRNA-based therapeutics to 

METiS Appoints Dr. Wei Xu as CSO to Accelerate mRNA Pipeline Development

Recently, the largest profiling of the global AI in the Drug Discovery industry made to date has been released in the form of an interactive IT-Platform and associated report by Deep Pharma Intelligence, a leading BioTech market research agency focused on sophisticated analytics, benchmarking and forecasting of emerging and frontier domains in the Pharmaceutical, BioTech and Healthcare industries.The AI in Drug Discovery platform features an interactive database of the Top 100 AI in Drug Discovery Experts, with information-rich profiles on the leading researchers, scientists, entrepreneurs and technologists committed to harnessing the potential of AI to tackle the complex challenges of drug discovery advancement.Dr. Hongming Chen, who is METiS Co-founder,President and Head of R&amp;D, ranked on the list ‘TOP 100 LEADERS of AI in Drug Discovery’.<div class="media-wrap image-wrap align-center" style="text-align:center"><img src="https://oss.metispharmaceuticals.cn/bc918d11436a88cafd649d6e726d62a3.png" width="685" height="405" style="width:685px;height:405px"/></div>Dr. Chen is a member of the National Academy of Engineering, a Fellow of the American Institute for Medical and Biological Engineering, a Fellow of the Controlled Release Society and a member of the Academy of Distinguished Chemical Engineers at the University of Texas at Austin. Dr. Chen holds a B.S. in Chemical Engineering from UT Austin and an M.S. and an Sc.D. in Chemical Engineering from Massachusetts Institute of Technology.Before joining METiS, Dr. Chen served as Chief Scientific Officer at Kala Pharmaceuticals, a biotech company she helped found in 2010. At Kala, she successfully translated a novel nanoparticle technology from bench to Phase III clinical trials and FDA approval, and helped to attract significant investments to the company, including an initial public offering in 2017. Prior to Kala, Dr. Chen helped start and build TransForm Pharmaceuticals, which was acquired by Johnson &amp; Johnson in 2005. She had also held various research positions at AstraZeneca and Merck.

剂泰医药联合创始人兼美国公司总裁、研发负责人陈红敏院士从全球众多创业者中脱颖而出，作为AI制药领域的企业家代表入选该100人名单。

Dr. Hongming Chen, who is METiS Co-founder,President and Head of R&D, ranked on the list ‘TOP 100 LEADERS AI in Drug Discovery’.

剂泰医药陈红敏院士入选“全球AI药物发现专家100人”

Dr. Hongming Chen ranked on the list ‘TOP 100 LEADERS of AI in Drug Discovery’

The 2023 World Artificial Intelligence Conference took place from July 6th to 8th at the Shanghai World Expo Center and the Shanghai World Expo Exhibition &amp; Convention Center. With the theme of &quot;Intelligent Connectivity Generating Future&quot;, this conference is co-sponsored by Shanghai Municipal Government, National Development and Reform Commission, Ministry of Industry and Information Technology, Ministry of Science and Technology, Cyberspace Administration of China, Chinese Academy of Sciences, Chinese Academy of Engineering, and China Association for Science and Technology. This conference is aimed at giving full play to its important role as “technology leader, application showcase, industry accelerator, and governance council”, bringing together profound wisdom, cutting-edge technologies, industrial trends, and human ecology in the global artificial intelligence field, and promoting the healthy and innovative development of artificial intelligence.On the morning of July 7th, as a representative of AI pharmaceutical companies, Dr. Chris Lai, the co-founder, and CEO of METiS Pharmaceuticals, participated upon invitation in the Financing and Investment sub-Forum of the 2023 World Artificial Intelligence Conference hosted by CICC and themed “Boundless Future, Booming of AIGC”. At the forum, he discussed the industry development and opportunities with the participants from the perspective of capital boosting the development of AI technology and shared his personal experiences and insights.<div class="media-wrap image-wrap"><img class="media-wrap image-wrap" src="https://oss.metispharmaceuticals.cn/de922bdb70d415b9841dc474220c7a20.png"/></div>The panel discussion was chaired by Zhang Qing, Managing Director of CICC Capital. Dr. Chris Lai, the co-founder and CEO of METiS Pharmaceuticals, John Qu, Global Senior Managing Partner of McKinsey &amp; Company, Han Wei, Chairman of AIForceTech, Ren Peng, Vice President at Perfect World and Head of Strategic Investment Department of, Nyx He, Senior Vice President and Partner at BrainCo, Wang Xiao, Partner at Unity Venture, and Zhang Suyang, Partner at Volcanics Venture, conducted a fruitful collision of ideas around the topic of“AI investment in the primary market at the dawn of a new wave”, actively offered advice and suggestions, and contributed their respective experiences and insights.<div class="media-wrap image-wrap"><img class="media-wrap image-wrap" src="https://oss.metispharmaceuticals.cn/9c62b8356adaf241e7897d474d3a758c.png"/></div>Dr. Lai introduced the key role of capital in the early development of AI companies, drawing on his experience as the founder of an AI-driven drug delivery and drug R&amp;D company. METiS Pharmaceuticals was founded by a group of MIT scientists and a member of the National Academy of Engineering (USA) in 2020. The founding of the company coincided with the outbreak of the COVID-19 pandemic, so all R&amp;D plans were put on hold. As a result, the founding team resolutely moved the core team from the United States to China, as well as their developing work of the platforms. Fortunately, METIS received adequate support from the Hangzhou Municipal Government in terms of start-up funds and laboratory placement, and therefore, quickly settled down in Hangzhou, China. Subsequently, the experimental data was quickly recognized by the capital market. For example, the delivery and transfection efficiency of nanocarriers designed by METiS is more than ten times higher than that of the industry giant Moderna. Meanwhile, METiS has addressed the delivery problems of the lungs, brain, tumors, immune organs, and muscles that are difficult for the industry to overcome. These impressive achievements obtained the support of leading funds, including Sequoia China, 5Y Capital, PICC Capital, and Lightspeed China. Thanks to the support of capital, METiS Pharmaceuticals has grown rapidly in the past three years and is now an innovative biotechnology company that has begun to take shape and focuses on AI-driven drug delivery and drug discovery.<div class="media-wrap image-wrap"><img class="media-wrap image-wrap" src="https://oss.metispharmaceuticals.cn/d4ea59defb2e554d181c1428fb4109b9.png"/></div>Dr. Lai is also very optimistic about the future of artificial intelligence technology. In recent years, he has witnessed the &quot;third drug revolution&quot; – the gene therapy drugs based on nucleic acid DNA and RNA codes, following the small molecule targeted drugs and antibody drugs. The mRNA vaccines developed by Moderna and BioNTech performed outstandingly during the COVID-19 pandemic, bringing nucleic acid gene drugs to the masses. The nano-delivery carrier LNP and RNA sequence have proved to be safer than expected, with unexpected drug effects, which has brought a wave of technological and financial benefits to the biopharmaceutical industry. METiS Pharmaceuticals has also joined the wave and quickly deployed the AI-driven nucleic acid delivery system design platform (AiLNP). Thanks to the contributions of the top scientists from MIT, AI technology platforms, and the capital market, METiS has created drug delivery and development capabilities that surpass the industry.Since the decoding of the human genome in 2000, the academic community has accumulated a large number of breakthroughs in molecular biology and genetic coding. These breakthroughs have led to significant progress in the development of nucleic acid-based gene drugs. The next 3-5 years will be a critical moment for the CGT industry, and the key technology to overcome the challenges is drug delivery. Those who will make huge technological breakthroughs and seize the market opportunities will be those who can make nano-delivery carriers that can accurately target and efficiently deliver nucleic acid drugs to disease tissues, and those who can cooperate deeply with major pharmaceutical multinationals.In addition, Dr. Lai looks forward to active support from the supervision authorities for the clinical development of such innovative drugs. He believes that with the efforts of pharmaceutical companies and the investment of capital, China will become a leader in the “third drug revolution” and build a gene drug ecosystem that will promote the R&amp;D of more innovative drugs and bring more good drugs to patients.

从资本助推AI技术发展的角度，和与会者共同探讨了行业发展和机遇，并分享个人经验和见解。

Discussing the industry development and opportunities with the participants from the perspective of capital boosting the development of AI technology and shared his personal experiences and i

剂泰医药赖才达博士出席2023世界人工智能大会投融资主题论坛

METiS CEO Dr. Chris Lai Attends the 2023 World Artificial Intelligence Conference Financing and Investment Sub-Forum

&quot;Humanity has never ceased in its pursuit of technology, and in turn, the advance of science and technology has also pushed the boundaries of business and reshaped our society. Today, we are witnessing an overwhelming emergence of new technologies, including artificial intelligence, quantum computing, chip manufacturing, medical biology, and controllable nuclear fusion, many of which are on their cusp of explosive growth. Meanwhile, amidst the hustle and bustle of scientific and technological progress, we need to understand: What kind of huge changes or impacts will technology bring to human beings? What kind of guidelines do pioneers who master cutting-edge technologies need to adhere to, to ensure that new technologies can promote the continued prosperity and development of mankind?”On March 30, the 2023 Fortune Global Tech Forum was held in Guangzhou. The Fortune Global Tech Forum is an annual international technology event hosted by Fortune. The event brings together executives from leading global companies, scholars who are at the forefront of technological progress in their respective fields, high-profile technology entrepreneurs, and well-known technology investors to share insights and forecast trends on hot topics such as the computing power economy, ChatGPT, electric vehicles, carbon neutrality, the digital economy, chip manufacturing, healthcare, and artificial intelligence.The forum&#x27;s theme is &quot;New Frontiers: Change and Resilience&quot; , which highlights the important trends in the global technology industry. This forum provides a unique opportunity for business executives, entrepreneurs, and investors to engage with the leaders of the digital revolution and discuss how to shape the future world.Dr.Wenshou Wang, the co-founder and COO of METiS Pharmaceuticals, was honored to represent METiS Pharmaceuticals upon the invitation to attend the Forum, and in the sub-forum titled &quot;the Future of Healthcare,&quot; Dr. Wang joined Clay Chandler, the executive editor for Asia at Fortune, Cheryl Cui, the co-founder and CEO of Bota Bio, Shuhao Wen, the co-founder and president of XtalPi Inc., and Huanqing Gu, the founder and president of the Stemcell United Ltd.(SCU), to discuss how innovative technologies can empower and enhance healthcare, and explore the cutting-edge new trends, in the context of the rapid development of science and technology.Dr. Wang remarked that the development of new drugs is becoming increasingly time-consuming and costly at present. He asserted that AI technology will revolutionize the pharmaceutical industry by automating the drug development process and making it more effective. “Rather than relying on blind trial-and-error methods, AI can provide a more purposeful approach to drug development, reducing the need for trial and error. Additionally, automating the manual tasks will significantly improve research and development efficiency.’’ he further explained. <div class="media-wrap image-wrap align-center" style="text-align:center"><img class="media-wrap image-wrap align-center" src="https://oss.metispharmaceuticals.cn/5450dc113804b2362d895fdc6d3f9f22.jpg" width="718.667px" height="478px" style="width:718.667px;height:478px"/></div><div class="media-wrap image-wrap align-center" style="text-align:center"><img class="media-wrap image-wrap align-center" src="https://oss.metispharmaceuticals.cn/47198948d72248feb51b321a310283e5.jpg" width="718px" height="474px" style="width:718px;height:474px"/></div>Dr. Wenshou Wang, the co-founder and COO of METiS Pharmaceuticals, sharing his insights at the forum&quot;AI + drug delivery&quot; technology will overcome the technological bottlenecks of conventional drug R&amp;D, and are poised to become the key to developing a new generation of treatment for the future, exemplified RNA therapeutics. The technology refers to the precise delivery of drugs and gene therapies to target organs, tissues and cells to cure diseases. On the other hand, in the development of new small molecule drugs, drug delivery technology can also improve pharmaceutical preparations/formulations of existing drugs, so as to develop new small molecule drugs with lower toxicity and better efficacy in a faster and more efficient manner. METiS is pushing the boundaries of drugs with the world&#x27;s leading technology platform for targeted drug delivery, which has diverse application potentials and offers excellent market prospects. About FORTUNEFortune is a globally influential business media organization that focuses on reporting on the ever-changing business landscape. It is renowned for its well-respected lists, such as the Fortune Global 500.Fortune has the unparalleled capability and influence to bring together top business leaders, opinion leaders, policymakers, and experts from various industries. From exclusive dinners to large-scale business and financial conferences, Fortune&#x27;s events are meticulously planned and executed to ensure the utmost quality. Renowned economists and CEOs of multinational corporations participate in these gatherings to discuss innovative technologies and cutting-edge industries, as well as hot issues related to corporate development. By fostering the consensus and foresight, these events help to expand the influence of the host cities, and enable the participants to work together towards extraordinary achievements. Leveraging its strategic focuses, high-level cross-industry interactions, and insights from a professional editorial team, Fortune offers exciting conferences and innovative activities.About METiS（METiS Pharmaceuticals）METiS is an innovative biotechnology company driven by artificial intelligence (AI) that harnesses targeted drug delivery technology to develop more effective drugs for patients. Through the integration of cutting-edge AI technology and traditional pharmaceutical R&amp;D, METiS aims to accelerate the R&amp;D of innovative drugs in a more efficient and precise way, while leveraging the core technology platforms to support the entire pharmaceutical ecosystem and lead industry innovation. Note: Part of the content and pictures come from www.fortunechina.com

共同探讨在科技飞速发展的背景下，创新技术如何赋能和助力医疗健康及未来健康的前沿新趋势

To discuss how innovative technologies can empower and enhance healthcare, and explore the cutting-edge new trends, in the context of the rapid development of science and technology.

剂泰医药受邀出席2023年《财富》全球科技论坛，共话未来健康前沿趋势

METiS Attends 2023 Fortune Global Tech Forum, Sharing Insights on Future Health Trends

剂泰医药（METiS）是全球首家以人工智能驱动药物递送和药物发现的生物技术公司，集合人工智能、机器学习和量子模拟等先进技术，旨在实现更有效的创新递送材料设计、候选药物选择和制剂设计、“可编程核酸药物”开发与核酸递送设计。

核心技术

业务|Business

管线|Pipeline

剂泰医药陈红敏院士入选“全球AI药物发现专家100人”

剂泰医药赖才达博士出席2023世界人工智能大会投融资主题论坛

剂泰医药受邀出席2023年《财富》全球科技论坛，共话未来健康前沿趋势